Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2018 01:35 ET | Source: ALK Abello

Three-month interim report (Q1) 2018

Bemærk venligst, at kvartalsrapporten kun foreligger på engelsk. Performance for the period (unaudited) Financial results in Q1 were better than expected and as a result, ALK has...
May 04, 2018 01:35 ET | Source: ALK Abello

Three-month interim report (Q1) 2018

Performance for the period (unaudited) Financial results in Q1 were better than expected and as a result, ALK has improved its full-year financial outlook. Q1 saw good progress with ALK’s four...
May 01, 2018 07:40 ET | Source: ALK Abello

Dato for offentliggørelse af delårsrapport for første tre måneder (Q1) 2018 for ALK og webcast

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) offentliggør delårsrapport for første tre måneder (Q1) 2018 fredag den 4. maj 2018. ALK afholder samme dag kl. 13.30 (CEST) en telefonkonference for...
May 01, 2018 07:40 ET | Source: ALK Abello

Release date of three-month interim report (Q1) 2018 and audio cast

On Friday, 4 May 2018, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its interim report for the three months ended 31 March 2018. ALK will host a meeting for analysts and...
April 17, 2018 21:00 ET | Source: ALK Abello

ALKs partner i Japan, Torii, indgår prisaftale for ny tablet mod japansk cedertræsallergi

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) har i dag meddelt, at selskabets partner i Japan, Torii Pharmaceutical Co., Ltd, har indgået en prisaftale med de japanske myndigheder for...
April 17, 2018 21:00 ET | Source: ALK Abello

ALK’s partner for Japan, Torii, secures pricing for new Japanese cedar SLIT-tablet

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its partner for Japan, Torii Pharmaceutical Co., Ltd., has agreed a price with authorities and secured a listing on Japan’s National...
April 11, 2018 06:40 ET | Source: ALK Abello

ALK announces allergy diagnostic partnership with Rellergen in China

ALK gains rights to market Rellergen’s Bio-IC technology in more than 190 hospitals across ChinaBio-IC technology offers fast, convenient and inexpensive allergy diagnosis on siteChina’s allergy...
March 20, 2018 11:44 ET | Source: ALK Abello

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): I henhold til artikel 19 i EU forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af...
March 20, 2018 11:44 ET | Source: ALK Abello

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the...
March 20, 2018 11:19 ET | Source: ALK Abello

Grant of share options and performance shares to members of the Board of Management and key employees

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): Share option programmeAccording to the guidelines for incentive payments adopted at the Company's annual general meeting on 12 March 2018, the Board of...